Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis

doi:10.1007/s11136-019-02296-5

Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis

科研成果: 期刊稿件 › 文章 › 同行评审

源语言	英语
页（从-至）	369-380
页数	12
期刊	Quality of Life Research
卷	29
期	2
DOI	https://doi.org/10.1007/s11136-019-02296-5
出版状态	已出版 - 2月 1 2020
已对外发布	是

!!!ASJC Scopus Subject Areas

公共卫生、环境和职业健康

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.1007/s11136-019-02296-5

其它文件与链接

引用此

@article{37d615c6d674423bb4d0d6cf929a0b1b,

title = "Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis",

keywords = "Ixekizumab, Psoriasis, Quality of life, SF-36",

note = "Publisher Copyright: {\textcopyright} 2019, Springer Nature Switzerland AG.",

year = "2020",

month = feb,

day = "1",

doi = "10.1007/s11136-019-02296-5",

language = "English",

volume = "29",

pages = "369--380",

journal = "Quality of Life Research",

issn = "0962-9343",

publisher = "Springer Netherlands",

number = "2",

}

TY - JOUR

T1 - Ixekizumab treatment and the impact on SF-36

T2 - results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis

PY - 2020/2/1

Y1 - 2020/2/1

KW - Ixekizumab

KW - Psoriasis

KW - Quality of life

KW - SF-36

UR - http://www.scopus.com/inward/record.url?scp=85074468701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074468701&partnerID=8YFLogxK

U2 - 10.1007/s11136-019-02296-5

DO - 10.1007/s11136-019-02296-5

M3 - Article

C2 - 31655974

AN - SCOPUS:85074468701

SN - 0962-9343

VL - 29

SP - 369

EP - 380

JO - Quality of Life Research

JF - Quality of Life Research

IS - 2

ER -

Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis

!!!ASJC Scopus Subject Areas

联合国可持续发展目标

访问文件

其它文件与链接

指纹

引用此